SCHEMBL3977044

SCHEMBL3977044

CC1(C)CC=C(c2nc(C3(O)CCOCC3)ccc2N)CC1

nearest known ligand 0.54

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
TBK1 Q9UHD2 1/20 0.34
PDE10A Q9Y233 1/20 0.33
KDM5B Q9UGL1 1/20 0.32
CSF1R P07333 4/20 0.32
KIT P10721 1/20 0.30
FLT3 P36888 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3980585 0.89 KDM5B (0.36) TBK1KDM5BCSF1R
SCHEMBL3977039 0.85 TBK1 (0.36) TBK1KDM5BCSF1RKITFLT3
SCHEMBL3973514 0.82 TBK1 (0.33) TBK1KDM5BCSF1RKITFLT3
SCHEMBL3977368 0.79 KDM5B (0.31) KDM5B
SCHEMBL14385126 0.77 CSF1R (0.46) CSF1RKITFLT3
SCHEMBL16320664 0.77 CSF1R (0.31) CSF1RKIT
SCHEMBL3981173 0.76 KDM5B (0.33) TBK1KDM5BCSF1R
SCHEMBL16320575 0.75 CSF1R (0.37) CSF1RKIT
SCHEMBL3164439 0.74
SCHEMBL3980584 0.74 KDM5B (0.35) TBK1KDM5BCSF1RKITFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9394289-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-07-19 US disclosed
EP-2016070-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-01-13 EP disclosed
US-20140378457-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-12-25 US disclosed
US-8859602-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2014-10-14 US disclosed
EP-2016070-A1 INHIBITORS OF C-FMS KINASE Janssen Pharmaceutica, N.V. (BE) 2009-01-21 EP disclosed
WO-2007124319-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 WO disclosed
US-20070249680-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378457-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES TBK1 1205/4885PDE10A 2963/4885KDM5B 1516/4885
US-20070249680-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES TBK1 1205/4885PDE10A 2963/4885KDM5B 1516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.